Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (15151)	1/7/2005 6:18:14 PM
From: Icebrg	Read Replies (2) of 52153

Protein-Bound Particle Drugs, for Metastatic Breast Cancer Friday January 7, 6:11 pm ET [Doesn't the label look a little bit strange? "Prior therapy should have included an anthracycline" ???] - ABRAXANE(TM), First Solvent-Free, Albumin-Bound Paclitaxel Nanoparticles, Requires No Premedication and Almost Doubles Response Rate Compared With Taxol(R) in Metastatic Breast Cancer - SCHAUMBURG, Ill., Jan. 7 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. (Nasdaq: APPX - News) and American Bioscience, Inc. (ABI) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRAXANE(TM) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer. ABRAXANE(TM) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next